Mycophenolsyre Tillomed (Mycophenolic Acid)

The drug selectively blocks inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for de novo guanosine nucleotide synthesis. Lymphocytes rely on this pathway for DNA replication; inhibition reduces guanosine pools, thereby suppressing the activation and proliferation of T and B cells.

Dosing is individualized and must be determined by the prescribing clinician based on the specific indication, patient weight, renal function, and concomitant therapies. Patients should follow the exact regimen provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. The drug may carry risks to the fetus or infant, and clinicians usually recommend avoiding use unless the potential benefit justifies the potential risk. Women of child‑bearing potential should discuss contraception and treatment options with their physician.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with azathioprine, another antimetabolite, mycophenolic acid provides more selective inhibition of lymphocyte proliferation and often achieves higher efficacy in preventing transplant rejection, though both share risks of bone‑marrow suppression and infection. Choice depends on the clinical scenario, tolerability and physician preference.

Store the product at ambient temperature, preferably below 25 °C, in the original packaging. Protect it from moisture, excessive heat and direct sunlight. Keep the container tightly closed and out of reach of children.

Mycophenolsyre Tillomed is administered orally. The tablets (or capsules, depending on the specific dosage form) are swallowed whole with water, usually twice daily, unless otherwise directed by the prescribing clinician.

Serious adverse events include opportunistic infections such as Pneumocystis jirovecii pneumonia, progressive multifocal leukoencephalopathy (PML), and severe bone‑marrow suppression leading to aplastic anemia or pancytopenia. Prompt medical attention is required if signs of infection, unexplained bruising, or neurological symptoms develop.

Patients with known hypersensitivity to mycophenolic acid or any excipients, those with uncontrolled severe infections, and individuals receiving live vaccines should avoid the drug. Caution is also advised in patients with significant renal or hepatic impairment, and it is contraindicated in pregnancy unless absolutely necessary.